GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
binimetinib + STA-4783 Sensitive: D – Preclinical
Oncogene - 1 week (New D)
|
binimetinib + STA-4783 Sensitive: D – Preclinical
Oncogene - 1 week - (New D)
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
STA-4783 Sensitive: D – Preclinical
Oncogene - 1 week (New D)
|
STA-4783 Sensitive: D – Preclinical
Oncogene - 1 week - (New D)
|
GNAQ mutation
|
Melanoma
|
GNAQ mutation
|
Melanoma
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
selumetinib Sensitive: C2 – Inclusion Criteria
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
trametinib Sensitive: C2 – Inclusion Criteria
|
trametinib Sensitive: C2 – Inclusion Criteria
|
GNAQ mutation
|
Melanoma
|
GNAQ mutation
|
Melanoma
|
vorinostat Sensitive: C2 – Inclusion Criteria
|
vorinostat Sensitive: C2 – Inclusion Criteria
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
pembrolizumab Sensitive: C3 – Early Trials
|
pembrolizumab Sensitive: C3 – Early Trials
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
cabozantinib capsule Sensitive: C3 – Early Trials
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
AEB071 Sensitive: C3 – Early Trials
|
AEB071 Sensitive: C3 – Early Trials
|
GNAQ mutation
|
RCC
|
GNAQ mutation
|
RCC
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
GNAQ mutation
|
Melanoma
|
GNAQ mutation
|
Melanoma
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
trametinib + dabrafenib Sensitive: C3 – Early Trials
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
AEB071 + AHT956 Sensitive: D – Preclinical
|
AEB071 + AHT956 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
Tris DBA Sensitive: D – Preclinical
|
Tris DBA Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
FR900359 Sensitive: D – Preclinical
|
FR900359 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
AEB071 + CGM097 Sensitive: D – Preclinical
|
AEB071 + CGM097 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
everolimus + AEB071 Sensitive: D – Preclinical
|
everolimus + AEB071 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
binimetinib + AEB071 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
JQ-1 Sensitive: D – Preclinical
|
JQ-1 Sensitive: D – Preclinical
|
GNAQ mutation
|
Uveal Melanoma
|
GNAQ mutation
|
Uveal Melanoma
|
PD-0325901 + AEB071 Sensitive: D – Preclinical
|
PD-0325901 + AEB071 Sensitive: D – Preclinical
|